Meeting
2024 ASCO Annual Meeting
Xevinapant with radiation and concurrent carboplatin and paclitaxel in patients ineligible for cisplatin with locoregionally advanced squamous cell carcinoma of the head and neck (EXtRaCT study).
Authors
Nabiel Ali Mir
The University of Chicago, Chicago, IL
Nabiel Ali Mir , Aditya Juloori , Paul Swiecicki , Rohan Reddy Katipally , Nishant Agrawal , Elizabeth A. Blair , Daniel J. Haraf , Alexander T. Pearson , Everett E. Vokes , Ari Joseph Rosenberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT06110195
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr TPS6126)
DOI
10.1200/JCO.2024.42.16_suppl.TPS6126
Abstract #
TPS6126
Poster Bd #
435b
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
NCI 9448: Phase I study of trametinib in combination with chemoradiation for KRAS-mutant non-small cell lung cancer.
First Author: Steven H. Lin
Poster
2024 ASCO Annual Meeting
An Indian real-world experience of intravenous fosnetupitant-palonosetron (IV NEPA) in preventing delayed and extended delayed CINV.
First Author: Hanmant V. Barkate
Poster
2023 ASCO Annual Meeting
XRay Vision: A phase 3 study of xevinapant plus radiotherapy (RT) for high-risk, cisplatin-ineligible patients with resected, locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
First Author: Robert L. Ferris
Poster
2021 ASCO Annual Meeting
TRYHARD, a randomized phase II trial (RTOG Foundation 3501) of concurrent accelerated radiation plus cisplatin (cis) with or without lapatinib (Lap) for stage III- IV Non-HPV head and neck carcinoma (HNC).
First Author: Stuart J. Wong